{
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc.",
    "description": "Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of cardiovascular diseases and conditions. Founded in 2007, Capricor is dedicated to advancing its proprietary product candidates, particularly its lead candidate, CAP-1002, which is designed for the treatment of Duchenne muscular dystrophy (DMD) and is being explored for other indications such as myocardial infarction and heart failure. The company's unique approach involves the use of allogeneic cardiosphere-derived cells (CDCs), which are derived from cardiac tissue and possess regenerative properties that can promote healing and repair of damaged tissues. Capricor's commitment to research and development is underscored by its collaborations with academic institutions and key industry partners to enhance its clinical programs. The company aims to address significant unmet medical needs in the fields of cardiology and neuromuscular diseases, striving to improve patient outcomes and quality of life through its innovative therapies. With a strong pipeline and a focus on advancing its clinical trials, Capricor is poised to make a meaningful impact in the biotechnology sector and improve the lives of patients suffering from serious health conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2007",
    "website": "https://www.capricor.com",
    "ceo": "Linda Marb\u00e1n, Ph.D.",
    "social_media": {
        "twitter": "https://twitter.com/CapricorTx",
        "linkedin": "https://www.linkedin.com/company/capricor-therapeutics/"
    },
    "investor_relations": "https://www.capricor.com/investor-relations/",
    "key_executives": [
        {
            "name": "Linda Marb\u00e1n, Ph.D.",
            "position": "CEO"
        },
        {
            "name": "Robert E. H. K. O. Hsieh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CAP-1002"
            ]
        }
    ],
    "seo": {
        "meta_title": "Capricor Therapeutics, Inc. | Innovative Cardiovascular Therapies",
        "meta_description": "Learn about Capricor Therapeutics, Inc., a biotechnology company focused on developing innovative therapies for cardiovascular diseases. Explore their lead product CAP-1002 and its potential in treating serious conditions.",
        "keywords": [
            "Capricor",
            "Biotechnology",
            "Cardiovascular",
            "Duchenne Muscular Dystrophy",
            "CAP-1002",
            "Regenerative Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Capricor Therapeutics known for?",
            "answer": "Capricor Therapeutics is known for developing innovative therapies for cardiovascular diseases and Duchenne muscular dystrophy."
        },
        {
            "question": "Who is the CEO of Capricor?",
            "answer": "Linda Marb\u00e1n, Ph.D. is the CEO of Capricor Therapeutics, Inc."
        },
        {
            "question": "Where is Capricor headquartered?",
            "answer": "Capricor is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What is Capricor's lead product?",
            "answer": "Capricor's lead product is CAP-1002."
        },
        {
            "question": "When was Capricor founded?",
            "answer": "Capricor was founded in 2007."
        }
    ],
    "competitors": [
        "AMRN",
        "BMY",
        "NVTA",
        "SRPT"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "REGN",
        "EXAS"
    ]
}